Market closedADR

PureTech Health/$PRTC

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About PureTech Health

PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.

Ticker

$PRTC
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Boston, United States

Employees

90
Website
www.puretechhealth.com

PureTech Health Metrics

BasicAdvanced
$408M
-
-$0.30
1.00
-

$408M

1

$34.00

$17.00

4.8K

3.679

3.633

43.722

47.267

-6.80%

-13.39%

-22.07%

10,168.605

1.06

1.06

-39.326

-96.01%

78.63%

-64.83%

-23.47%

What the Analysts think about PureTech Health

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for PureTech Health stock.

PureTech Health Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

PureTech Health Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

PureTech Health News

AllArticlesVideos
PureTech Appoints UBS as UK Corporate Broker

PureTech Appoints UBS as UK Corporate Broker

Business Wire·1 week ago
PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

PureTech's Deupirfenidone (LYT-100) Slowed Lung Function Decline in People with Idiopathic Pulmonary Fibrosis (IPF) as Measured by Forced Vital Capacity (FVC), Achieving the Primary and Key Secondary Endpoints in the ELEVATE IPF Phase 2b Trial

Business Wire·4 weeks ago
PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting

Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRTC

$

Sign up or log in to buy
Capital at risk
Market closedADR

Upcoming events

No upcoming events

FAQs

What’s the current market cap for PureTech Health stock?

PureTech Health (PRTC) has a market cap of $408M as of January 15, 2025.

What is the P/E ratio for PureTech Health stock?

The price to earnings (P/E) ratio for PureTech Health (PRTC) stock is 0 as of January 15, 2025.

Does PureTech Health stock pay dividends?

No, PureTech Health (PRTC) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next PureTech Health dividend payment date?

PureTech Health (PRTC) stock does not pay dividends to its shareholders.

What is the beta indicator for PureTech Health?

PureTech Health (PRTC) has a beta rating of 1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.